Development and provision of innovative medicines for rare diseases, including recombinant and plasma-derived products for coagulation disorders, immune deficiencies, autoimmune and inflammatory diseases, hereditary angioedema, and alpha-1 antitrypsin deficiency.
C
CSR Analysis score
The organization is among the 50% most committed organizations, excluding the top 20%, among comparable organizations.
EmpCo Directive — September 27, 2026
We analyzed the websites of over 250,000 companies, including CSL Behring's, to extract CSR initiatives and communications containing risky environmental claims.
Greenwashing risk score + your position within your sector
+250,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: August 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Orphan Europe
B
Development and provision of medicines for rare diseases in endocrinology, oncology-hematology, and metabolic therapy areas.
LFB
B
Development, manufacturing, and marketing of plasma-derived biopharmaceuticals for serious and often rare diseases in hemostasis, immunology, and intensive care.
Chiesi
B
Development and commercialization of innovative therapeutic solutions in respiratory, neonatology, transplantation, and rare diseases. The company conducts R&D, production, and distribution of pharmaceuticals.
Initiatives identified among leaders
Création d’une fondation en 2005 pour promouvoir santé et aider patients en maladies respiratoires/néonatales.
“Chiesi SAS a créé une fondation en 2005 pour promo...” - ChiesiÉvénements et enquête pour stagiaires et alternants en France
“LFB organise des événements internes appelés « Sha...” - LFBCertification B Corp et engagement vers neutralité carbone d’ici 2035
“Chiesi SAS est certifiée B Corp depuis 2019, intég...” - Chiesi62% of similar organizations communicate on CSR issues
+788 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports